Status:
UNKNOWN
MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer
Lead Sponsor:
Alexandria University
Conditions:
Rectum Cancer
Eligibility:
All Genders
Brief Summary
Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic MRI have split scar sign are included. Patients will have tot...
Detailed Description
Patients with middle or low rectal cancer who have T3-4 and/ or N+ will be included. Patients will receive neoadjuvant chemoradiation in the form of pelvic irradiation by 50.4 thousands grays together...
Eligibility Criteria
Inclusion
- middle and low rectal cancer
Exclusion
- Distant metastasis
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04745091
Start Date
February 1 2021
End Date
June 30 2022
Last Update
February 9 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.